JBC Advanced Glycation Endproducts

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Flodby, P.
Right arrow Articles by Xanthopoulos, K. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Flodby, P.
Right arrow Articles by Xanthopoulos, K. G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Volume 271, Number 40, Issue of October 4, 1996 pp. 24753-24760
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Increased Hepatic Cell Proliferation and Lung Abnormalities in Mice Deficient in CCAAT/Enhancer Binding Protein alpha *

(Received for publication, January 19, 1996, and in revised form, July 3, 1996)

Per Flodby Dagger , Carrolee Barlow §, Helen Kylefjord §, Lars Ährlund-Richter Dagger and Kleanthis G. Xanthopoulos Dagger §

From the Dagger  Karolinska Institute, Department of Biosciences at Novum S-141 57 Huddinge, Sweden and the § National Center for Human Genome Research, CGTB, National Institutes of Health, Bethesda, Maryland 20892-1852

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

CCAAT/enhancer binding protein alpha  (C/EBPalpha ) is a transcription factor that has been implicated in the regulation of cell-specific gene expression mainly in hepatocytes and adipocytes but also in several other terminally differentiated cells. It has been previously demonstrated that the C/EBPalpha protein is functionally indispensable, as inactivation of the C/EBPalpha gene by homologous recombination in mice results in the death of animals homozygous for the mutation shortly after birth (Wang, N., Finegold, M. J., Bradley, A., Ou, C. N., Abdelsayed, S. V., Wilde, M. D., Taylor, L. R., Wilson, D. R., and Darlington, G. J. (1995) Science 269, 1108-1112). Here we show that C/EBPalpha -1-mice have defects in the control of hepatic growth and lung development. The liver architecture is disturbed, with acinar formation, in a pattern suggestive of either regenerating liver or pseudoglandular hepatocellular carcinoma. Pulmonary histology shows hyperproliferation of type II pneumocytes and disturbed alveolar architecture. At the molecular level, accumulation of glycogen and lipids in the liver and adipose tissues is impaired, and the mutant animals are severely hypoglycemic. Levels of c-myc and c-jun RNA are specifically induced by several fold in the livers of the C/EBPalpha -/- animals, indicating an active proliferative stage. Furthermore, immunohistologic detection with an antibody to proliferating cell nuclear antigen/cyclin shows a 5-10 times higher frequency of positively stained hepatocytes in C/EBPalpha -/- liver. These results suggest a critical role for C/EBPalpha in vivo for the acquisition of terminally differentiated functions in liver including the maintenance of physiologic energy homeostasis.


INTRODUCTION

CCAAT/enhancer binding protein alpha  (C/EBPalpha )1 is the prototype member of the C/EBP family and belongs to the basic leucine zipper class (bZIP) of transcription factors (2, 3, 4). All members of the C/EBP family have a C-terminally located basic leucine zipper domain that is responsible for DNA binding and dimerization (5). Several members of this family have been cloned from different species, for a review see Refs. 6, 7, that are able to both homodimerize and heterodimerize with each other and to bind the same C/EBP consensus DNA sites. These properties are reflected in the high degree of homology of the bZIP domain (8). By contrast, the transactivation and attenuation domains are located in the N-terminal part (9, 10, 11, 12), where a relatively low level of homology exists (8). Thus, the members of the C/EBP family are able to bind the same DNA sites but differ in their transacting and attenuating properties.

Expression of C/EBPalpha in rodents is restricted to certain tissues and cell types (8, 13, 14). High expression levels are detected in liver, white and brown adipose tissue, and placenta. C/EBPalpha is also expressed in the lung, mainly in differentiated type II cells (15), in the intestine where it is found in differentiated enterocytes (16), in the ovary during follicular development (17), and in myeloid cells (18). Furthermore, expression has been described in adrenal gland and skin (13), and at least in humans, also in pancreas and prostate (19). The basis for the restricted and differential expression pattern of the C/EBPalpha mRNA is regulation at the transcriptional level (14). The molecular mechanisms that control the expression of the C/EBPalpha gene have not been fully elucidated (20); however, the organization of the promoter has been studied in detail (21, 22, 23). The results from these studies suggest an autoregulatory mechanism that contributes to the control of the expression of this gene (22, 23).

Studies in 3T3-L1 adipoblasts have provided evidence for reciprocal expression patterns of C/EBPalpha and c-myc (24). It has been suggested that this is the result of negative regulation of the C/EBPalpha gene exerted by c-myc. Repression is mediated through interactions of c-myc with the initiator element of the C/EBPalpha promoter (25, 26).

There are an increasing number of genes known to be subjected to transcriptional regulation by C/EBPalpha . Several of the target genes are expressed in a cell-specific manner, e.g. albumin in hepatocytes (27, 28) and uncoupling protein in brown adipocytes (29). Furthermore, many target genes such as aP2 and SCD-1 (30, 31), GLUT-4 (32), PEPCK (33), aldolase B (34), and acetyl-CoA carboxylase (35) are involved in carbohydrate and lipid metabolism pathways. In addition, it has been demonstrated by two different sets of experiments that C/EBPalpha is of central importance in the process of terminal differentiation of adipocytes. First, it was shown that C/EBPalpha antisense RNA blocks the differentiation of preadipocytes into adipocytes (36, 37). Second, overexpression of C/EBPalpha in different fibroblastic cell lines is sufficient to induce adipocyte differentiation (38, 39). C/EBPalpha can induce growth arrest in adipocytes suggesting that it may play a role in the regulation of the balance between proliferation and differentiation (24, 40). It is also conceivable that C/EBPalpha contributes to the maturation of hepatocytes and the maintenance of the differentiation state. Results from studies on regenerating liver after partial hepatectomy clearly show a dramatic decrease of the expression of C/EBPalpha , of at least 5-fold, during the proliferative phase (41, 42). Recently, growth arrest by C/EBPalpha was demonstrated by co-transfection of a C/EBPalpha expression vector in a variety of cell lines (12). The multiplicity of interactions of C/EBPalpha with a variety of regulatory elements of genes suggests a central role for C/EBPalpha in cell proliferation and differentiation and in key metabolic pathways.

To ascertain the role of the C/EBPalpha protein in vivo, we have generated C/EBPalpha -deficient mice by homologous recombination in ES cells. Here we report that C/EBPalpha is critical for the proper development of both the liver and the lung since animals deficient in C/EBPalpha display gross abnormalities in these organs and die within 10 h after birth. In accordance to a previous report (1), we also show that C/EBPalpha is indispensable for postnatal maintenance of systemic energy homeostasis and lipid storage. Furthermore, in nullizygous livers c-myc, c-jun, and beta -actin steady state RNA levels and PCNA/cyclin protein levels are increased suggesting an active proliferative state.


EXPERIMENTAL PROCEDURES

Construction of the Targeting Vector

A genomic clone including the C/EBPalpha gene was derived from an OLA 129-lambda GEM-12 genomic library by screening with a PstI/SstI 400-bp fragment representing the bZIP region of C/EBPalpha as a probe. A 7.3-kb EcoRI fragment from the 12.6-kb genomic clone was subcloned into a pBS ± vector (Stratagene). The subcloned fragment contains sequences 3.4 kb upstream and 1.2 kb downstream of the C/EBPalpha gene. The 5' EcoRI site in the fragment is derived from the lambda  GEM-12 linker, whereas the 3' site represents a genomic EcoRI site. An 1133-bp XhoI/HincII fragment, containing the neoR gene driven by a TK promoter, was derived from the vector pMC1neo poly(A) (Stratagene), optimized for neoR expression in ES cells (43). This fragment was blunt-end ligated into the MluI site within C/EBPalpha in the opposite direction compared with the transcriptional direction of the C/EBPalpha gene. To enable negative selection against random integration, a 1854-bp XhoI/HindIII fragment containing the HSV thymidine kinase gene driven by a polyoma virus enhancer (44) was inserted into the HindIII/SalI site of linker, 5' of the homologous genomic sequence.

Electroporation, Selection, and Screening of ES Cells

The targeting vector was linearized by PvuI digestion. 20 µg was used to electroporate 20 × 106 R1 ES cells (45) with a Bio-Rad Gene Pulser at 260 V and 500 microfarads. Transfected R1 cells were then plated on gamma-irradiated G418-resistant mouse embryo fibroblast feeder cells. Around 48 h after transfection selective media containing 675 µg of G418/ml (50% active substance) was added. After another 24 h new media also containing 2 µM Ganciclovir (Cymevene, Syntex Inc.) was added. New selective media (G418 + Ganciclovir) was added daily, and after 10 days surviving clones were transferred individually to round-bottomed 96-well plates, trypsinized, and then seeded onto two different flat-bottomed 96-well plates, one with feeder cells and one without feeder cells. The cells on the former plate were trypsinized prior to confluency, suspended in fetal calf serum, 10% dimethyl sulfoxide, and frozen in the plate, whereas the cells on the latter plate were allowed to reach confluency and then used for DNA extraction according to the microextraction method described by Ramírez-Solis et al. (46). DNA was then analyzed by Southern blot to screen for homologous recombination. In brief, microextracted genomic DNA was digested by 15 units/well of BamHI (high concentration, Life Technologies, Inc.) in a total volume of 50 µl in a digestion mix including 100 µg of bovine serum albumin/ml, 1 mM spermidine, and RNase A at 50 µg/ml. Digested DNA was separated on 0.6% agarose gels, transferred to Hybond N membranes (Amersham Corp.), and hybridized to a 1.3-kb EcoRI/BamHI fragment (E1.3B), representing the region 3' of the genomic sequence in the targeting construct (Fig. 1D). The 1133-bp XhoI/HincII TK promoter-Neo-poly(A) fragment, derived from pMC1neo poly(A), was used as a probe to verify that only one copy of the targeting construct had been inserted into the genome.


Fig. 1. Strategy for disruption of the C/EBPalpha gene. A, restriction map of the 12.6-kb genomic fragment containing the C/EBPalpha gene. The 7.3-kb EcoRI fragment used for targeting vector construction and the 1.3-kb EcoRI/BamHI probe (E1.3B) are indicated. C/EBPalpha is an intronless gene. The restriction sites indicated are as follows: N, NruI; M, MluI; H, HindIII; E, EcoRI; Bg, BglII, and B, BamHI. B, targeting vector construction. The neoR gene was inserted into the MluI site in the opposite direction compared with the C/EBPalpha gene, and the tk gene was inserted 5' of the genomic sequence. The neoR gene is driven by a HSV-TK promoter, whereas the tk gene is driven by a duplicated mutant polyoma virus enhancer (PYF441 Enh). C-D, homologous recombination between the targeting construct and the C/EBPalpha allele and the targeted allele resulting from homologous recombination. Small x in the mRNA represents stop codons introduced in the C/EBPalpha transcript by the insertion of the neoR gene. E, Southern blot analysis of transfected and selected R1 ES cell clones. The 10.5-kb wild type BamHI fragment from the nontargeted allele and the 5.7-kb fragment from the mutated allele are shown. F, Southern blot analysis of a litter from a heterozygote intercrossing. DNA was digested with BamHI and probed with E1.3B. The genotypes are indicated above the lanes. +/+, wild type; +/-, heterozygous; and -/-, nullizygous animals. G-H, Northern blot analysis of liver RNA from a litter resulting from a heterozygote intercrossing (same individuals as in F). Hybridization with a 400-bp probe of the C/EBPalpha bZIP region detects both the 2.8-kb wild type C/EBPalpha transcript and the 3.9-kb C/EBPalpha :Neo fusion transcript (G). A neoR probe detects the 1.1-kb Neo(+) mRNA, transcribed by the TK promoter and the fusion transcript in +/- and -/- animals (H).
[View Larger Version of this Image (36K GIF file)]

Generation of C/EBPalpha -/- Mice

R1 ES cells with one targeted C/EBPalpha allele were injected into C57BL/6 blastocysts and implanted into F1 (CBA × C57BL/6) foster mothers. Male chimeras were mated to C57BL/6 females to verify germ line transmission by coat color. Agouti offspring was screened for presence of the targeted C/EBPalpha allele by Southern blot on tail DNA, according to Laird et al. (47) using the E1.3B probe described above. Heterozygous offspring was then intercrossed to obtain homozygous mice with both C/EBPalpha alleles targeted.

Analysis of Serum Glucose and Lipid Levels

Blood was obtained by decapitation and bleeding onto heparinized 35-mm cell culture plates. The blood was collected with a small rubber policeman, and 20 µl was added to 400 µl of 0.2% NaF, 0.9% NaCl solution. Blood was centrifuged, and the glucose concentration in the supernatant was measured in a Hitachi 917 spectrophotometer (Huddinge University Hospital) according to standard methods.

Northern and Western Blot Analysis

Total RNA was isolated from liver using the Ultraspec RNA isolation system (Biotecx, Houston, TX), according to the manufacturer's instructions. 20 µg of total RNA/well was fractionated on 1% agarose/MOPS/formaldehyde gels and transferred to Hybond N filters. Prehybridization was performed at +42 °C in 50% formamide, 1.5 × SSPE, 10 × Denhardt's, 1% SDS, 0.5 mg/ml fragmented and denatured salmon sperm DNA, 0.2 mg/ml tRNA. Hybridization was performed at +42 °C with same buffer composition as above with the exception that Denhardt's was lowered to 5 × and dextran sulfate was added to 10%. Probe concentration in the hybridization was 2 × 106 cpm/ml buffer. Densitometric analysis of the Northern blot signals was performed using a Molecular Dynamics instrument and software.

Liver nuclear lysates for Western blot analysis were prepared by adding an equal volume of 2 × polyacrylamide gel electrophoresis reducing sample buffer to purified nuclei pellets (48) and then carefully sonicated to shear DNA and heated at +100 °C for 3 min. After correction for differences in protein concentrations between the samples, 20 µl of the nuclear lysates were loaded on SDS-polyacrylamide gel electrophoresis minigels. Western blot analysis was then performed as described (42). Detection of total protein on the transfer membranes was used as a control of protein loading and was performed with the enhanced chemiluminescence protein biotinylation system (Amersham Corp.) according to the manufacturer's recommendations.

Morphological and Immunohistologic Analysis

Tissues were fixed in 10% neutralized formalin or frozen in liquid nitrogen. Sections for analysis were prepared either with a cryostat or a microtome after paraffin embedding. Fixed and paraffin-embedded sections were stained with hematoxylin and eosin using standard protocols. Oil Red O staining of fat in liver and white and brown adipose tissue, periodic acid-Schiff staining of glycogen, and PCNA immunostaining (monoclonal antibody number 19A2, Innovex Biosciences) in liver were performed using standard protocols.


RESULTS

Generation of C/EBPalpha -/- Mice

To inactivate the C/EBPalpha gene, a mutation was generated by inserting a HSV-TK promoter-driven neoR poly(A)+ gene into the unique MluI site at position +701 in C/EBPalpha . Within the C/EBPalpha gene there are several in frame AUG translation start codons, but only two AUG codons (+130 and +491) are used in vivo, giving rise to two proteins, p42 and p30 (49, 50). Another AUG codon further downstream of the MluI site was shown to be used only when the other upstream AUG codons were deleted. By inserting the neoR gene into the MluI site in the opposite direction compared with the C/EBPalpha gene, we introduced stop codons in all three reading frames downstream of both AUG start sites. Thus, only truncated protein products, lacking the DNA binding and dimerizing domain (bZIP), are expected to be translated from the transcript of the targeted C/EBPalpha gene. Furthermore, since the nuclear localization signal resides in the bZIP domain, the produced truncated proteins will not be imported into the nucleus and will probably be rapidly degraded in the cytoplasm. Fig. 1, A and B, shows the construction of the targeting vector, including a flanking tk gene to reduce the number of ES cell clones with randomly integrated vector (44). Correct insertion of the neoR gene was verified by sequencing of the NeoR:C/EBPalpha boundaries (data not shown). As shown in Fig. 1, C and D, homologous recombination between the targeting vector and the C/EBPalpha gene will result in the introduction of a new BamHI site within C/EBPalpha , resulting in a BamHI fragment of decreased size (5.7 kb) compared with the wild type 10.5-kb fragment. A representative Southern blot analysis of microextracted DNA from transfected and double selected R1 ES cell clones is shown in Fig. 1E. In total, seven positive ES clones were obtained with a frequency of homologous recombination of 1:38. The positive clones were expanded and analyzed further with a neoR probe. To substantiate that the event of homologous recombination had been correct, EcoRI-digested DNA was probed with an XhoI/HindIII neoR fragment from pMC1Neo poly(A) that resulted in the expected hybridizing 3' fragment of 3.25 kb and one 5' fragment of 7.3 kb. In addition, BamHI digestion resulted in the expected 5.7-kb fragment, verifying that only one copy of the targeting vector was present in the genome (data not shown). Two positive clones (S12 and S18) were used for blastocyst injections and generation of chimeric males. Germ line transmitting chimeric animals were derived from both targeted ES clones and were used to establish two independent heterozygous lines. The same phenotypic effects were observed in -/- animals derived from both lines.

Heterozygous animals were interbred to obtain mice homozygous for the mutated alleles. Fig. 1G shows a Southern blot analysis, using the E1.3B probe, of a litter resulting from a representative heterozygote intercross. The outcome of the intercrossings shows that there is no significant negative selection against the mutation during embryogenesis since C/EBPalpha -/- animals were born approximately at the expected 1:4 Mendelian ratio. A small reduction in the numbers of -/- animals was observed, but this decrease was not statistically significant (27% +/+, 51.8% +/-, 21.2% -/-, n = 425; chi 2 test, p > 0.10).

Transcription of the Inactivated C/EBPalpha Locus Occurs in the Absence of the C/EBPalpha Protein

In addition to inactivation of the locus, our targeting strategy with insertion of the neoR gene in the opposite orientation within the C/EBPalpha gene was designed to test whether efficient and sustained transcription of the locus is possible without the positive autoregulation by the C/EBPalpha protein. In such case a 3.9-kb transcript should be detected in C/EBPalpha -/- mice using either a C/EBPalpha or a neoR probe. The data presented in Fig. 1G, demonstrate that a neoR:C/EBPalpha fusion transcript of 3.9 kb appears as a result of transcription of the targeted C/EBPalpha allele, not only in the +/- mice but also in the -/- animals. As expected the fusion transcript is also detected by the neoR probe as shown in Fig. 1H, suggesting that C/EBPalpha gene transcription occurs in the absence of the C/EBPalpha protein. Perhaps other C/EBP family members are able to compensate for the loss of C/EBPalpha . This notion is supported by transient transfection experiments that show transactivation of the C/EBPalpha promoter by C/EBPbeta (22). Finally, the appearance of both bands in the heterozygous animals shows that both C/EBPalpha alleles are transcribed.

To demonstrate that the targeted event resulted in total elimination of the C/EBPalpha protein, liver nuclei lysates were analyzed by Western blot analysis that was performed on pups from several litters. The results from one such experiment are shown in Fig. 2A, verifying that the C/EBPalpha protein is completely absent in livers from nullizygous animals. Two other members of the family, C/EBPbeta and C/EBPdelta , were analyzed in parallel. As shown in Fig. 2, B and C, no overt differences could be demonstrated between the three genotypes.


Fig. 2. Western blot analysis of liver nuclear lysates from a heterozygote intercrossing litter. a, detection by specific antibodies directed against C/EBPalpha shows no detectable levels of C/EBPalpha protein in -/- animals. b and c, the same liver nuclear lysates as in a using antibodies against C/EBPbeta and C/EBPdelta illustrate that both of these proteins are expressed in all littermates. d, total amount of protein in each lane visualized by the protein biotinylation system (Amersham Corp.). CRM indicates nonspecific cross-reacting material. The same filter was used in b-d.
[View Larger Version of this Image (70K GIF file)]

Most C/EBPalpha Nullizygous Mice Die in the First 10 h after Birth, but Some Die at Birth

Littermates in most litters showed no obvious differences at birth. However, in about 20% of the litters, most of the C/EBPalpha -/- pups died virtually at delivery. The majority of these born almost dead (BAD) mice died immediately after birth, while a few were able to survive for a shorter period of approximately 30 min. Dissection of these animals showed the presence of bubbles in their stomachs. BAD mice are, in general, born in large litters (9.4 ± 1.6 pups, n = 10 litters). The reason why this phenomenon only occurs in about 20% of the C/EBPalpha -/- mice and only in large litters remains unclear.

As shown in Table I, there was a small but significant difference in body weight at birth between the pups. Normal and heterozygous pups had the same weight, whereas nullizygous pups weighed 10% less than their littermates. This weight difference is further augmented at 7-10 h where the +/+ and +/- pups have increased their body weight by 15-20%, while the C/EBPalpha -/- animals have not gained any weight at all. These nullizygous animals, although apparently normal at birth, gradually become weaker, and most of them were never able to start feeding. After 7-10 h severe symptoms of hypoglycemia, such as lethargy and shivering, were manifested, and these animals died soon after. Although some -/- pups clearly were able to start feeding, they did not survive more than 20 h. Dissection revealed that these mice had milk in their stomachs. Finally, in very few cases (less than 1%) nullizygous mice were able to survive for a considerably longer period of up to 4 weeks of age. These long term survivors are severely retarded in development. At around 2 weeks of age they are about half the size of their littermates. These animals are very thin and skin problems were observed with flaking from large areas of the body before fur outgrowth. This is a very rare but reproducible phenotype.

Table I.

Body weights and blood glucose levels

Animals are divided into two groups, newborns and another group where the nullizygous pups are near death, approximately 7-10 h after birth.
Genotype Weight Glucose

g mM
At birth + /+ 1.29  ± 0.15, n = 14 1.24  ± 0.34, n = 5
+ /- 1.31  ± 0.15, n = 28 1.20  ± 0.54, n = 15
 - /- 1.18  ± 0.13, n = 14 1.20  ± 0.57, n = 3
7-10 h postpartum + /+ 1.53  ± 0.14, n = 21 4.33  ± 1.18, n = 12
+ /- 1.51  ± 0.15, n = 27 5.09  ± 1.65, n = 16
 - /- 1.24  ± 0.13, n = 18 0.13  ± 0.05, n = 7

Since C/EBPalpha has been shown to regulate several genes involved in carbohydrate and lipid metabolism, the dramatic effects on the early postnatal survival in nullizygous mice could be due to low blood glucose levels, similar to the phenotype displayed by the C14Cos albino deletion mice (51). We therefore tested the blood serum levels of glucose in newborn litters and in litters at the time point when knockout animals usually die (7-10 h). The results from these tests, shown in Table I, clearly demonstrate that there is a dramatic drop in blood glucose levels some hours after birth in the -/- animals when compared with their +/- and +/+ littermates. Low glucose levels between 0.1 and 0.2 mM are detected within 1 h postpartum (data not shown), but the animals survive for an additional 6-10 h. This is consistent with the results of an earlier report (1). We have also investigated the serum lipid levels at birth and around 10 h postnatally. No statistically significant differences for either cholesterol or triglyceride levels were detected.

C/EBPalpha Nullizygous Mice Have Disturbed Liver Architecture, Immature Pulmonary Phenotype, and Fail to Accumulate Lipids

Histologic analysis of litters from heterozygous intercrosses, performed either at birth or at 7-10 h postpartum, revealed striking differences in liver, lung, and adipose tissues when -/- animals were compared with the other two genotypes. The hepatic architecture of the nullizygous mutants was severely distorted with acinar formation. The liver morphology also had a clear resemblance to regenerating liver following partial hepatectomy or pseudoglandular hepatocellular carcinoma. The number of biliary canaliculi in the C/EBPalpha -/- liver is considerably higher compared with both +/+ and +/- liver (Fig. 3, upper lane). Hepatocytes from nullizygous animals appear to have a smaller cytoplasm/nucleus ratio, which may explain the dilated bile canaliculi. However, no choleostasis or bile thrombi were observed. Liver sections of littermates using periodic acid-Schiff stained for glycogen at birth and 10 h postpartum showed that the normal and heterozygous animals contained substantial amounts of glycogen, whereas the -/- mice had drastically decreased but detectable levels (data not shown). It has been suggested that the distorted architecture may be due to the deficiency in fat and glycogen stores in the cytoplasm that results in smaller hepatocyte volumes (1). An alternative explanation may be that genes involved in the cytoskeleton formation in hepatocytes are targets of C/EBPalpha regulation resulting in an imperfect three-dimensional structure.


Fig. 3. Liver architecture and lung morphology are distorted in C/EBPalpha -/- animals. A representative series of histologic sections of liver and lung tissues stained with hematoxylin and eosin. Note the acinar formation in the livers of C/EBPalpha -/- mutants. Pulmonary histology of newborn littermates indicates h. Hyperproliferation of type II pneumocytes in C/EBPalpha -/- mice and results in reduction in the alveolar airspace (arrow, middle right panel) and interstitial thickening (arrow, lower right panel).
[View Larger Version of this Image (116K GIF file)]

Lipid accumulation in both white and brown adipose tissue is dependent on C/EBPalpha (36, 37). To investigate the effects of C/EBPalpha deficiency in lipid storage, we performed histologic analysis of adipose tissue. In newborn mice there are detectable fat depots in white adipose tissue localized to the inguinal region and considerable amounts in the brown adipose tissue. Although cells mass and general histologic appearance of the brown adipose tissue was not altered, the fat depot was greatly reduced in the C/EBPalpha -/- mice, as seen by Oil Red O staining (data not shown). Thus, unlike the situation in the liver, C/EBPalpha deficiency does not affect the overall brown adipose tissue morphology but is rather specific for the accumulation of lipids.

All C/EBPalpha -/- mice displayed irregular pulmonary histopathology. Although location of the lungs of C/EBPalpha -/- mice was comparable with the normal littermates, embryonic, fetal, and neonatal development of the airways was abnormal (Fig. 3). In mutant mice the lungs showed hyperproliferation of type II pneumocytes and bronchiolization of the alveoli. The primitive-appearing lung resembles the appearance of the lungs of premature human infants. C/EBPalpha -/- mice, particularly of the BAD type, had clinical symptoms of a respiratory nature, suggesting a role for C/EBPalpha in the normal development of the lung. However, in spite of the immature histologic phenotype of the mutant lungs, we did not detect any significant changes at the protein expression level of some key respiratory epithelial cell-specific molecular markers. Thus, unlike the pulmonary pathology observed in TGF-beta 3 and GM-CSF nullizygous mice (52, 53) C/EBPalpha deficiency did not alter the expression patterns of surfactant protein C (proSP-C), thyroid transcription factor-1 (TTF1), and Clara cell secretory protein (CC10).2 Although we did not see any effects on the expression of these important proteins that are markers for a highly differentiated state of the lung, the observed respiratory problems could be explained by an inadequate expression of other surfactant apoproteins than SF-C. Interestingly, the promoter of the major surfactant protein, SP-A, was recently shown to contain three potential C/EBPalpha binding sites (54). Since surfactants are lipoproteins, another possible explanation for respiratory dysfunction could be that the lipid production in the lung is affected by the C/EBPalpha deficiency, resulting in inadequate production of functional surfactant.

Induction of c-myc and c-jun in the Liver of C/EBPalpha -/- Mice

The distorted liver architecture of the C/EBPalpha -/- mice is indicative of an active proliferative state. To investigate the molecular mechanisms that may underlie these differences, we analyzed the transcription rates and steady state levels of genes that may be important in maintenance of the balance between proliferation and differentiation in hepatocytes. We chose to test the expression levels of albumin and alpha -fetoprotein as markers for hepatocyte differentiation and tumor development, respectively. In addition, we tested beta -actin, c-myc, and c-jun that correlate well with active cellular proliferation. Total liver RNA isolated at birth and several hours later was compared among littermates. A representative Northern analysis is shown in Fig. 4, and densitometric analysis of these experiments is shown in Table II. mRNA levels of albumin were reduced in C/EBPalpha -/- animals, especially in the livers of newborn animals. By contrast, alpha -fetoprotein expression levels were increased about 2-fold. This is indicative of a more de-differentiated state of the C/EBPalpha -/- hepatocytes. Levels of the beta -actin RNA were induced by 3-fold suggesting a proliferative state. However, the most predominant change, in addition to changes in the expression of genes involved in glycogenesis that were demonstrated in an earlier report (1), was the induction of c-myc and c-jun RNA (Fig. 4 and Table II). Steady state c-jun RNA levels from livers of both newborn and 7-h-old C/EBPalpha -/- mice were increased by about 10-fold. Induction of c-myc RNA was pronounced in livers of 7-h-old -/- mice (Fig. 4 and Table II). These findings are consistent with the patterns of expression observed in the early regenerating mouse liver. In addition, early stages of experimentally induced hepatocellular carcinoma in rodents display a similar expression pattern for these genes (55).


Fig. 4. Pronounced induction of c-jun and c-myc RNA in C/EBPalpha -/- mice. Northern blot analysis of RNA extracted from livers of newborn and 7-h-old animals. A total of 3-4 animals of each genotype were used from each time point in three independent experiments. A representative Northern blot is shown.
[View Larger Version of this Image (70K GIF file)]

Table II.

Relative densitometric values obtained from Northern blots

The values were normalized to 18 S rRNA controls. Densitometric values of -/- animals are set arbitrarily to 100 units. Mean values ± S.D. are shown.
RNA +/+ +/-  -/-

Albumin
 Newborn 273  ± 112 255  ± 97 100  ± 40
 7 h 239  ± 98 231  ± 77 137  ± 76
Actin
 Newborn 32  ± 13 36  ± 9 100  ± 37
 7 h 27  ± 3 26  ± 10 76  ± 33
AFP
 Newborn 43  ± 26 48  ± 23 100  ± 42
 7 h 51  ± 21 56  ± 26 79  ± 39
c-myc
 Newborn 62  ± 27 71  ± 35 100  ± 49
 7 h 16  ± 7 11  ± 5 68  ± 36
c-jun
 Newborn 12  ± 5 14  ± 6 100  ± 31
 7 h 9  ± 4 7  ± 6 88  ± 37

Since C/EBPalpha and c-myc are reciprocally regulated in adipocytes (24) and hepatocytes (26), it is possible that c-myc induction is a direct effect of C/EBPalpha deficiency. However, a more likely explanation is that c-myc induction reflects the critical role of this molecule in mitogenesis and transformation (56) and, together with the c-jun induction, is indicative of the proliferative stage of the C/EBPalpha -/- hepatocytes.

Because proliferating hepatocytes and hepatocellular carcinoma cells have induced levels of proliferating cell nuclear antigen (PCNA/cyclin) (57), we performed immunohistostaining with an antibody to PCNA/cyclin. The results presented in Fig. 5 illustrate a 5-10 times higher frequency of positively stained hepatocytes in C/EBPalpha -/- liver, further supporting the notion that an increased portion of the nullizygous hepatocytes are in the G1/S phase of the cell cycle. Thus, loss of C/EBPalpha has an effect on the proliferative potential of hepatocytes in vivo.


Fig. 5. Liver sections stained with an antibody to PCNA/cyclin and counter-stained with hematoxylin. Note the increased staining in C/EBPalpha -/- sections. Original magnification × 157.5.
[View Larger Version of this Image (105K GIF file)]


DISCUSSION

C/EBPalpha Is Essential for Postnatal Survival

We have inactivated the C/EBPalpha gene in mice by the introduction of stop codons downstream of the two AUG translation start sites used in the C/EBPalpha gene. These stop codons are situated within the neoR gene sequence that was inserted in the opposite direction to the C/EBPalpha transcription unit. Thus, this manipulation will not result in a gene inactivation at the transcriptional level but rather at the translational level. This targeting strategy has enabled us to obtain new information about the mechanisms of transcription of the C/EBPalpha gene. First, both alleles of the C/EBPalpha are actively transcribed since two transcripts of different sizes are detected in heterozygote animals. Thus, we conclude that the C/EBPalpha gene is not imprinted in mice. Second, the presence of a C/EBPalpha :NeoR fusion transcript in the nullizygous liver indicates that the previously suggested autoregulatory mechanism of the C/EBPalpha gene can be substituted by other C/EBP members. It is likely that C/EBPbeta is responsible, since this C/EBP family member has been shown to transactivate C/EBPalpha promoter-reporter constructs in vitro (22) and is expressed at high levels in nullizygous liver (Fig. 2). The steady state level of the C/EBPalpha :NeoR fusion transcript is lower compared with the C/EBPalpha wild type transcript in heterozygote liver. This may be due to a less efficient transcription of the mutated allele or the fusion transcript is more unstable. Alternatively, C/EBPalpha may not be required for its own expression, but rather it may augment transcription from its own promoter through interactions with other transcription factors, as suggested for the human gene (23). C/EBPalpha deficiency may result in lower levels of C/EBPalpha gene expression.

Mice nullizygous for C/EBPalpha are born to term. We have not found any significant deviation from the expected Mendelian ratio of nullizygous mice in the litters. This is different compared with a recent report (1). Perhaps this reflects the different genetic background of the back crossings of the two nullizygous mutants. Another remote possibility is that in the study of Wang et al. (1) C/EBPalpha gene inactivation was accomplished by the deletion of the entire C/EBPalpha coding region plus 2.4 kb of upstream sequences. This deletion could in turn have affected important regulatory elements associated with other genes important for embryogenesis, particularly since a strong DNase I-hypersensitive site is located in this region (20).

Disturbed Liver Architecture

The effects of the C/EBPa gene inactivation are dramatic but are not manifested until after birth, when metabolic functions characteristic for the differentiated liver are initiated in the newborn animal. C/EBPalpha nullizygous mice begin to runt and die shortly after birth. About 20% of the mutant mice die consistently at birth or within 30 min postpartum while the rest survive only for a period of 7-10 h. All mice show gross liver histologic abnormalities and hypoglycemia and failure to accumulate lipids or fat. The drastically reduced amounts of stored glycogen and fat in liver and adipose tissues observed in newborn nullizygous mice are highly likely to be an important reason for the weakness of these animals and is probably the reason for the lower body weight at birth. Stored energy fuels, which are normally built up prior to birth in liver and adipose tissues, are very important glucose sources for the newborn animal before the suckling period. Furthermore, the ability to realize gluconeogenesis is necessary for maintaining energy homeostasis. Genes coding for PEPCK, glucose-6-phosphatase, and tyrosine aminotransferase, all highly expressed in liver, are crucial for gluconeogenesis. We have found that the transcription rate of the PEPCK gene, a known C/EBPalpha target gene, is reduced to approximately 30% in C/EBPalpha -/- liver (data not shown). Thus, inadequate gluconeogenesis is likely to be another reason for the rapidly appearing low blood glucose levels in C/EBPalpha -/- mice. This hypothesis is further substantiated by the fact that another gene involved in the reversible gluconeogenic/glycolytic pathways, aldolase B, displays a transcription rate in C/EBPalpha -/- liver that is only about 30% of the rate found in +/+ and +/- liver (data not shown). Interestingly, aldolase B has recently been shown to be a target gene for C/EBPalpha (34). The maternal glucose in the blood of the newborn C/EBPalpha -/- animals is likely consumed very rapidly, since we detect very low blood glucose levels in these mice already 1-h postpartum. The apparent lack of energy makes the nullizygous mice so weak that they very often are unable to start suckling. Even individuals that are able to start some feeding do not generally survive for any longer periods. This might indicate metabolic dysfunctions other than storage of energy fuels and gluconeogenesis. It has been suggested that severe hypoglycemia is the primary reason for death (1). However, glucose injections cannot rescue the mutant mice for more than a couple of days (1). Problems with absorption of nutrients do not appear to be likely, because histology of the gut does not reveal any abnormalities,3 a view that is supported by a previous analysis (1). Thus, the exact mechanisms underlying the death of C/EBPalpha -/- animals is not completely clear.

The fact that triacylglycerol stores are not found in either liver or in adipose tissue suggests that genes important for lipid accumulation, expressed in both these tissues, may be the targets of C/EBPalpha regulation. We envisaged that the identification of such target genes regulated by C/EBPalpha will reveal the mechanisms of action of this molecule in lipid storage.

The effects of C/EBPalpha gene inactivation are pleiotropic. As mentioned under ``Results,'' in very rare cases C/EBPalpha -/- animals are able to survive for longer periods of up to 4 weeks. These mice will be the subject for further analysis, enabling studies of the effects of the C/EBPalpha gene inactivation in later stages of mouse development. For instance, the brain would be a tissue of interest since C/EBPalpha expression has been shown to appear first a few weeks postpartum (14, 58) and the Aplysia C/EBP has been implicated in long term potentiation of neurons (59). In addition, it has been postulated that C/EBPalpha may play a role in keratinocyte development (13). The long term C/EBPalpha -/- survivors may provide some information on this aspect since the few individuals that survived that long appear to have skin problems.

Retarded Pulmonary Development

The C/EBPalpha nullizygous mice also differ from their littermates in that they exhibit retarded pulmonary development. In particular, hyperproliferation of type II pneumocytes is clearly visible in neonatal lungs. About 20% of the C/EBPalpha nullizygous mice die within 20-30 min after birth, apparently from respiratory failure. However, all nullizygous animals showed histologic evidence of delayed maturation of type II epithelial cells. This phenotype is analogous to the pulmonary effects of targeted disruption of a homeodomain gene, GSH-4 (60), TGF-beta 3, and GM-CSF nullizygous mice (52, 53). Recent evidence suggested a role for C/EBPalpha in the development and maintenance of the surfactant system in lung type II cells (15). Nonetheless, since both C/EBPbeta and C/EBPdelta are expressed in the lung, it is possible that these proteins compensate for the loss of C/EBPalpha in proper regulation of surfactant protein genes in lung epithelial cells. By contrast, deficiency of lipid production in alveoli, due to the absence of C/EBPalpha , may interfere with inadequate production of functional surfactant molecules. This could contribute to the respiratory problems associated with the nullizygous mice and may be the primary reason for the cause of the immediate death observed in C/EBPalpha -/- animals of the BAD type.

Induced Hepatic Proliferation in C/EBPalpha -/- Mice

Earlier experiments suggested that the C/EBPalpha gene product may be a component of the balance between proliferation and differentiation (24, 40, 41, 42). The loss of C/EBPalpha results in a dramatic induction of c-myc, c-jun, and beta -actin RNA in the liver. These genes correlate well with active cellular proliferation. Histology of the liver shows that hepatocytes in the nullizygous mice appear healthy with smaller cytoplasm/nuclei ratio. The morphology of the -/- liver is indicative of either regenerating liver or pseudoglandular hepatocellular carcinoma. PCNA/cyclin immunostaining experiments that demonstrate excessive accumulation of PCNA/cyclin in C/EBPalpha -/- hepatocytes further support the notion that a substantial portion of the nullizygous hepatocytes are in the G1/S phase of the cell cycle. Taken together these data suggest a role for C/EBPalpha as ``orthogene'' necessary for acquisition and maintenance of the differentiated hepatocyte phenotype. However, heterozygous mutants do not show, so far, any evidence of hepatocellular carcinoma formation. It is clear that some of the activities of the C/EBPalpha gene are compensated for by other members of the C/EBP family (i.e. as is the case of activation of C/EBPalpha gene promoter). However, the severity of the C/EBPalpha -/- phenotype certainly suggests that this protein is indispensable for many other critical functions. The availability of this mutant and eventually a tissue-specific C/EBPalpha knockout line will greatly facilitate our understanding of the function of this critical molecule in vivo.


FOOTNOTES

*   This work was supported by grants from the Swedish Cancer Society, the Karolinska Institute, the Stockholm City Council, the Swedish Medical Research Council, Petrus and Augusta Hedlunds Stiftelse, and Axel and Margaret Ax:son Johnssons Stiftelse. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   To whom correspondence should be addressed. Tel.: 301-435-2831; Fax: 301-496-7184; E-mail: kgx{at}nchgr.nih.gov.
1   The abbreviations used are: C/EBP, CCAAT/enhancer binding protein; BAD, born almost dead; neoR, neomycin phosphotransferase; PCNA, proliferating cell nuclear antigen; PEPCK, phosphoenolpyruvate carboxykinase; TK, thymidine kinase; bZIP, basic leucine zipper class; bp, base pair; kb, kilobase pair; MOPS, 4-morpholinepropanesulfonic acid.
2   J. Whitshett, personal communication.
3   P. Flodby and K. G. Xanthopoulos, unpublished data.

Acknowledgments

We thank Irma Jansson for culturing and transfecting ES cells. We also thank José Inzunza for excellent technical assistance and contribution at the early stages of this work. Dr. Andras Nagy is acknowledged for the R1 ES cell line. Drs. Mark Brantly, David Kleiner, Sylvia Fojo, and Melissa Rosenfeld have provided expert advice and critical input.


REFERENCES

  1. Wang, N., Finegold, M. J., Bradley, A., Ou, C. N., Abdelsayed, S. V., Wilde, M. D., Taylor, L. R., Wilson, D. R., Darlington, G. J. (1995) Science 269, 1108-1112 [Abstract/Free Full Text]
  2. Johnson, P. F., Landschulz, W. H., Graves, B. J., McKnight, S. L. (1987) Genes Dev. 1, 133-146 [Abstract/Free Full Text]
  3. Grayson, D. R., Costa, R. H., Xanthopoulos, K. G., Darnell, J. E. (1988) Science 239, 786-788 [Abstract/Free Full Text]
  4. Landschulz, W. H., Johnson, P. F., Adashi, E. Y., Graves, B. J., McKnight, S. L. (1988) Genes Dev. 2, 786-800 [Abstract/Free Full Text]
  5. Landschulz, W. H., Johnson, P. F., McKnight, S. L. (1988) Science 240, 1759-1764 [Abstract/Free Full Text]
  6. Johnson, P. F. (1990) Cell Growth & Differ. 1, 47-51 [Medline] [Order article via Infotrieve]
  7. Xanthopoulos, K. G., Mirkovitch, J. (1993) Eur. J. Biochem. 216, 353-360 [Medline] [Order article via Infotrieve]
  8. Williams, S. C., Cantwell, C. A., Johnson, P. F. (1991) Genes Dev. 5, 1553-1567 [Abstract/Free Full Text]
  9. Friedman, A. D., McKnight, S. L. (1990) Genes Dev. 4, 1416-1426 [Abstract/Free Full Text]
  10. Pei, D., Shih, C. (1991) Mol. Cell. Biol. 11, 1480-1487 [Abstract/Free Full Text]
  11. Nerlov, C., Ziff, E. B. (1994) Genes Dev. 8, 350-362 [Abstract/Free Full Text]
  12. Hendricks-Taylor, L. R., Darlington, G. J. (1995) Nucleic Acids Res. 23, 4726-4733 [Abstract/Free Full Text]
  13. Birkenmeier, E. H., Gwynn, B., Howard, S., Jerry, J., Gordon, J. I., Landschulz, W. H., McKnight, S. L. (1989) Genes Dev. 3, 1146-1156 [Abstract/Free Full Text]
  14. Xanthopoulos, K. G., Mirkovitch, J., Decker, T., Kuo, C. F., Darnell, J. E., Jr. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 4117-4121 [Abstract/Free Full Text]
  15. Li, F., Rosenberg, E., Smith, C. I., Notarfrancesco, K., Reisher, S. R., Shuman, H., Feinstein, S. I. (1995) Am. J. Physiol. 13, 241-247
  16. Chandrasekaran, C., Gordon, J. I. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8871-8875 [Abstract/Free Full Text]
  17. Piontkewitz, Y., Enerbäck, S., Hedin, L. (1993) Endocrinology 133, 2327-2333 [Abstract]
  18. Scott, L. M., Civin, C. I., Rorth, P., Friedman, A. D. (1992) Blood 80, 1725-1735 [Abstract/Free Full Text]
  19. Antonson, P., Xanthopoulos, K. G. (1995) Biochem. Biophys. Res. Commun. 215, 106-113 [CrossRef][Medline] [Order article via Infotrieve]
  20. Xanthopoulos, K. G., Cannon, P. D., Robinson, G. S., Darnell, J. E., Jr. (1992) Eur. J. Biochem. 208, 501-509 [Medline] [Order article via Infotrieve]
  21. Christy, R. J., Kaestner, K. H., Geiman, D. E., Lane, M. D. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 2593-2597 [Abstract/Free Full Text]
  22. Legraverend, C., Antonson, P., Flodby, P., Xanthopoulos, K. G. (1993) Nucleic Acids Res. 21, 1735-1742 [Abstract/Free Full Text]
  23. Timchenko, N., Wilson, D. R., Taylor, L. R., Abdelsayed, S., Wilde, M., Sawadogo, M., Darlington, G. J. (1995) Mol. Cell. Biol. 15, 1192-1202 [Abstract]
  24. Freytag, S. O., Geddes, T. J. (1992) Science 256, 379-382 [Abstract/Free Full Text]
  25. Li, L., Nerlov, C., Prendergast, G., MacGregor, D., Ziff, E. (1994) EMBO J. 13, 4070-4079 [Medline] [Order article via Infotrieve]
  26. Antonson, P., Pray, M. G., Jacobsson, A., Xanthopoulos, K. G. (1995) Eur. J. Biochem. 232, 397-403 [Medline] [Order article via Infotrieve]
  27. Friedman, A. D., Landschulz, W. H., McKnight, S. L. (1989) Genes Dev. 3, 1314-1322 [Abstract/Free Full Text]
  28. Costa, R. H., Grayson, D. R., Xanthopoulos, K. G., Darnell, J. E., Jr. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 3840-3844 [Abstract/Free Full Text]
  29. Yubero, P., Manchado, C., Cassard-Doulcier, A. M., Hampel, T., Viflas, O., Inglesias, R., Giralt, M., Villarroya, F. (1994) Biochem. Biophys. Res. Commun. 198, 653-659 [CrossRef][Medline] [Order article via Infotrieve]
  30. Christy, R. J., Yang, V. W., Ntambi, J. M., Geiman, D. E., Landschulz, W. H., Friedman, A. D., Nakabeppu, Y., Kelly, T. J., Lane, M. D. (1989) Genes Dev. 3, 1323-1335 [Abstract/Free Full Text]
  31. Herrera, R., Ro, H. S., Robinson, G. S., Xanthopoulos, K. G., Spiegelman, B. M. (1989) Mol. Cell. Biol. 9, 5331-5339 [Abstract/Free Full Text]
  32. Kaestner, K. H., Christy, R. J., Lane, M. D. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 251-255 [Abstract/Free Full Text]
  33. Park, E. A., Roesler, W. J., Liu, J., Klemm, D. J., Gurney, A. L., Thatcher, J. D., Shuman, J., Friedman, A., Hanson, R. W. (1990) Mol. Cell. Biol. 10, 6264-6272 [Abstract/Free Full Text]
  34. Vallet, V., Bens, M., Antoine, B., Levrat, F., Miquerol, L., Kahn, A., Vandewalle, A. (1995) Exp. Cell Res. 216, 363-370 [CrossRef][Medline] [Order article via Infotrieve]
  35. Tae, H.-J., Luo, X, Kim, K.-H. (1994) J. Biol. Chem. 269, 10475-10484 [Abstract/Free Full Text]
  36. Samuelsson, L., Strömberg, K., Vikman, K., Bjursell, G., Enerbäck, S. (1991) EMBO J. 10, 3787-3793 [Medline] [Order article via Infotrieve]
  37. Lin, F. T., Lane, D. M. (1992) Genes Dev. 6, 533-544 [Abstract/Free Full Text]
  38. Lin, F.-T., Lane, M. D. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 8757-8761 [Abstract/Free Full Text]
  39. Freytag, S. O., Paielli, D. L., Gilbert, J. D. (1994) Genes Dev. 8, 1654-1663 [Abstract/Free Full Text]
  40. Umek, R. M., Friedman, A. D., McKnight, S. L. (1991) Science 251, 288-292 [Abstract/Free Full Text]
  41. Mischoulon, D., Rana, B., Bucher, N. L. R., Farmer, S. R. (1992) Mol. Cell. Biol. 12, 2553-2560 [Abstract/Free Full Text]
  42. Flodby, P., Antonson, P., Barlow, C., Blanck, A., Porsch-Hällström, I., Xanthopoulos, K. G. (1993) Exp. Cell Res. 208, 248-256 [CrossRef][Medline] [Order article via Infotrieve]
  43. Thomas, K. R., Capecchi, M. R. (1987) Cell 51, 503-512 [CrossRef][Medline] [Order article via Infotrieve]
  44. Mansour, S. L., Thomas, K. R., Capecchi, M. R. (1988) Nature 336, 348-352 [CrossRef][Medline] [Order article via Infotrieve]
  45. Nagy, A., Rossant, J., Nagy, R., Abramow-Newerly, W., Roder, J. C. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8224-8228 [Abstract/Free Full Text]
  46. Ramirez-Solis, R., Rivera-Perez, J., Wallace, J. D., Wims, M., Zheng, H., Bradley, A. (1992) Anal. Biochem. 201, 331-335 [CrossRef][Medline] [Order article via Infotrieve]
  47. Laird, P. W., Zijderveld, A., Linders, K., Rudnicki, M. A., Jaenisch, R., Berns, A. (1991) Nucleic Acids Res. 19, 4293 [Free Full Text]
  48. Hattori, M., Tugores, A., Veloz, L., Karin, M., Brenner, D. A. (1990) DNA Cell Biol. 9, 777-781 [Medline] [Order article via Infotrieve]
  49. Ossipow, V., Descombes, P., Schibler, U. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8219-8223 [Abstract/Free Full Text]
  50. Lin, F. T., MacDougald, O. A., Diehl, A. M., Lane, M. D. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9606-9610 [Abstract/Free Full Text]
  51. Tönjes, R. R., Xanthopoulos, K. G., Darnell, J. E. J., Paul, D. (1992) EMBO J. 11, 127-133 [Medline] [Order article via Infotrieve]
  52. Kaartinen, V., Voncken, J. W., Shuler, C., Warburton, D., Bu, D., Heisterkamp, N., Groffen, J. (1995) Nat. Genet. 11, 415-421 [CrossRef][Medline] [Order article via Infotrieve]
  53. Dranoff, G., Crawford, A. D., Sadelain, M., Ream, B., Rashid, A., Bronson, R. T., Dickersin, G. R., Bachurski, C. J., Mark, E. L., Whitsett, J. A., Mulligan, R. C. (1994) Science 264, 713-716 [Abstract/Free Full Text]
  54. Smith, C. I., Rosenberg, E., Reisher, S. R., Li, F., Kefalides, P., Fisher, A. B., Feinstein, S. I. (1995) Am. J. Physiol. 269, L603-L612 [Abstract/Free Full Text]
  55. Flodby, P., Liao, D.-Z, Blanck, A., Xanthopoulos, K. G., Porsch-Hällström, I. (1995) Mol. Carcinogen. 12, 103-109 [Medline] [Order article via Infotrieve]
  56. Evan, G. I., Littlewood, T. D. (1993) Curr. Opin. Genet. Dev. 3, 44-49 [CrossRef][Medline] [Order article via Infotrieve]